Discontinuation of Hypomethylating Agent Therapy in Patients with Myelodysplastic Syndromes or Acute Myelogenous Leukemia in Complete Remission or Partial Response: Retrospective Analysis of Survival after Long-term Follow-up

Hypomethylating agents (HMA), such as 5-azacitidine or decitabine, are currently used to treat patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) until treatment failure. However, the outcomes for patients who discontinue therapy after achieving partial response (PR) or co...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Leuk Res
Auteurs principaux: Cabrero, Monica, Jabbour, Elias, Ravandi, Farhad, Bohannan, Zach, Pierce, Sherry, Kantarjian, Hagop M., Garcia-Manero, Guillermo
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826042/
https://ncbi.nlm.nih.gov/pubmed/25828745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2015.03.006
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires